Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Budesonide 15 mg showed no clear difference in corticosteroid related adverse events compared with placebo (moderate certainty).
Budesonide 9 mg probably leads to lower induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with conventional steroids (moderate certainty).
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).
Budesonide 9 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeksThomsen 1998 compared with mesalamine (moderate certainty).
Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Budesonide 9 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI < 150) compared with mesalamine (moderate certainty).
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with mesalamine (low certainty).
Budesonide 3 mg showed no clear difference in corticosteroid related adverse events compared with placebo (low certainty).
Budesonide 9 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).
Budesonide 9 mg probably leads to higher clinical improvement (decrease in CDAI > 100 or total CDAI < 150) ‐… compared with placebo (moderate certainty).
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Budesonide 9 mg showed no clear difference in corticosteroid related adverse events compared with placebo (moderate certainty).
Budesonide 6 mg showed no clear difference in continued remission at 3 months compared with placebo (low certainty).
Budesonide 9 mg showed no clear difference in continued remission at 12 months compared with budesonide 6 mg (moderate certainty).
Budesonide 9 mg showed no clear difference in continued remission at 12 months compared with prednisolone 40 mg (low certainty).
It is very uncertain whether budesonide 6 mg changes continued remission at 12 months compared with mesalamine 3 g (very low certainty).
It is very uncertain whether budesonide 6‐9 mg changes continued remission at 12 months compared with azathioprine 2‐2.5 mg/kg (very low certainty).
Budesonide 3 mg probably leads to higher continued remission at 3 months compared with placebo (moderate certainty).
Budesonide 6 mg showed no clear difference in continued remission at 3 months compared with budesonide 3 mg (moderate certainty).